ArticleJournal of ovarian research2025
Ginsenoside Rg1 promotes the efficacy of human amnion-derived mesenchymal stem cells in alleviating chemotherapy-induced premature ovarian insufficiency in rats.
Article in Journal of ovarian research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Inflammatory remodeling of the ovarian microenvironment in premature ovarian insufficiency: mechanisms and therapeutic opportunities.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPremature ovarian insufficiency (POI) can cause multiple sequelae in young women and is currently incurable. Mesenchymal stem cell (MSC)-based treatment of POI shows great promise. However, some limitations affect their efficacy in POI treatment, and exploration of methods to improve their efficacy is necessary. This study aimed to explore whether Rg1 can improve the efficacy of human amnion-derived MSC (hAD-MSC) transplantation in the treatment of rats with chemotherapy-induced POI.
methodshAD-MSCs were isolated from human amnions. One hundred female SD rats were divided into control, POI, Rg1, hAD-MSCs and Rg1 + hAD-MSCs groups. POI rat models were first established by intraperitoneal injection of cisplatin, and then the rats in the hAD-MSCs and Rg1 + hAD-MSCs groups were injected with PKH26-labelled hAD-MSCs via tail veins, while the rats in the Rg1 and Rg1 + hAD-MSCs groups were intraperitoneally injected with Rg1. At 24 h, 4 and 8 weeks after cell transplantation, serum sex hormone levels, oestrous cycles, ovarian pathological changes, granulosa cell (GC) apoptosis and antiapoptotic and proapoptotic protein expression in ovaries were evaluated. A chemotherapy-induced injury model of GCs was established by treatment with cisplatin in vitro to investigate the underlying mechanisms.
resultshAD-MSC transplantation significantly increased Bcl-2 expression; decreased Bax, cleaved-caspase-3, cleaved-caspase-9 and cleaved-PARP expression; and inhibited GC apoptosis in POI ovaries, which reduced ovarian injury and improved ovarian function in chemotherapy-induced POI rats; and the effects of hAD-MSC transplantation were significantly improved by Rg1 combined with hAD-MSC transplantation. Moreover, the enhanced efficacy of hAD-MSCs by Rg1 combined with hAD-MSCs in the inhibition of ovarian GC apoptosis was demonstrated in a chemotherapy injury model of GCs induced by cisplatin in vitro. The mechanisms might involve the modulatory role of Rg1 on both transplanted hAD-MSCs and GCs in the ovaries of POI rats, which indirectly and directly promoted the antiapoptotic effects on ovarian GCs, respectively, and the PI3K/Akt-mitochondrial intrinsic pathway of apoptosis may be a vital target pathway involved in these processes.
conclusionRg1 may promote the efficacy of hAD-MSC transplantation in alleviating chemotherapy-induced POI in rats. Rg1 might be a novel adjuvant drug to promote the efficacy of MSCs in the treatment of chemotherapy-induced POI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.